• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Eastman Chemical Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    6/27/25 8:51:12 AM ET
    $EMN
    Major Chemicals
    Industrials
    Get the next $EMN alert in real time by email
    emn-20250627
    0000915389false00009153892025-06-272025-06-270000915389us-gaap:CommonStockMember2025-06-272025-06-270000915389emn:A1.875notesdueNovember2026Member2025-06-272025-06-27

    Eastman_Black_300dpi.jpg

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549

    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 or 15 (d) of The Securities Exchange Act of 1934

    Date of report (Date of earliest event reported):
    June 27, 2025

    EASTMAN CHEMICAL COMPANY
    (Exact Name of Registrant as Specified in Its Charter)
    Delaware 1-12626 62-1539359
    (State or Other Jurisdiction
    of Incorporation)
     (Commission File Number) (IRS Employer
    Identification No.)
    200 South Wilcox Drive 
    KingsportTennessee37662
    (Address of Principal Executive Offices)(Zip Code)
    (423) 229-2000
    (Registrant’s Telephone Number, Including Area Code)
      
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
        
     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
        
     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
        
     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class Trading Symbol(s)Name of each exchange on which registered
    Common Stock, par value $0.01 per share EMNNew York Stock Exchange
    1.875% Notes Due 2026EMN26New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    (d) On June 27, 2025, the Board of Directors (the “Board”) of Eastman Chemical Company (the “Company”) appointed Damon Audia as a director to serve until the Company’s 2026 Annual Meeting of Stockholders. He has been appointed to serve as a member of the Audit Committee, the Finance Committee, and the Environmental, Safety and Sustainability Committee of the Board. Mr. Audia will receive compensation consistent with the Company’s non-employee directors, which includes cash compensation and equity awards, as further described in the Company’s 2025 Proxy Statement filed with the Securities and Exchange Commission on March 21, 2025. Mr. Audia will also enter into an indemnification agreement with the Company.

    There are no arrangements or understandings between Mr. Audia and any other persons pursuant to which he was appointed as a director. Mr. Audia does not have any family relationships with any of the Company’s directors or executive officers. There are no transactions and no proposed transactions between Mr. Audia and the Company that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K.

    Item 7.01 Regulation FD Disclosure.

    On June 27, 2025, the Company issued a press release announcing Mr. Audia’s appointment to the Board as discussed in Item 5.02 of this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    Item 9.01 (d)    Exhibits

    Exhibit 99.1 is furnished pursuant to Item 9.01(d).

    99.1    Press Release announcing appointment of Damon Audia as a director.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)




     SIGNATURES


    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
     
      
    Eastman Chemical Company 
     
     By:/s/ Iké G. Adeyemi
    Iké G. Adeyemi
    Senior Vice President, Chief Legal Officer and Corporate Secretary
      Date: June 27, 2025


    Get the next $EMN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EMN

    DatePrice TargetRatingAnalyst
    4/28/2025$76.00Overweight → Neutral
    Analyst
    4/9/2025$91.00Sector Perform → Outperform
    RBC Capital Mkts
    4/4/2025$101.00Neutral → Buy
    Citigroup
    4/3/2025$105.00Neutral → Outperform
    Mizuho
    1/14/2025$115.00 → $109.00Neutral → Buy
    BofA Securities
    12/18/2024$118.00 → $104.00Buy → Neutral
    Citigroup
    11/26/2024$110.00 → $125.00Equal Weight → Overweight
    Wells Fargo
    10/16/2024$114.00 → $119.00Buy → Neutral
    BofA Securities
    More analyst ratings